Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial.

@article{Mansel2006RandomizedMT,
  title={Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial.},
  author={Robert E. Mansel and Lesley Fallowfield and Mark Kissin and Amit Goyal and Robert G. Newcombe and Jonathan M. Dixon and Constantinos Yiangou and Kieran Horgan and Nigel J. Bundred and Ian J. Monypenny and D. England and Mark Sibbering and Tholkifl I Abdullah and Lester Barr and Utheshtra Chetty and Dudley H Sinnett and Anne Fleissig and Dayalan Clarke and Peter Joseph Ell},
  journal={Journal of the National Cancer Institute},
  year={2006},
  volume={98 9},
  pages={599-609}
}
BACKGROUND Sentinel lymph node biopsy in women with operable breast cancer is routinely used in some countries for staging the axilla despite limited data from randomized trials on morbidity and mortality outcomes. We conducted a multicenter randomized trial to compare quality-of-life outcomes between patients with clinically node-negative invasive breast cancer who received sentinel lymph node biopsy and patients who received standard axillary treatment. METHODS The primary outcome measures… CONTINUE READING
Highly Influential
This paper has highly influenced 42 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS